NASDAQ:CRON Cronos Group (CRON) Stock Price, News & Analysis → Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (From InvestorPlace) (Ad) Free CRON Stock Alerts $2.93 +0.16 (+5.78%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$2.81▼$2.9650-Day Range$1.96▼$2.9452-Week Range$1.64▼$2.99Volume2.72 million shsAverage Volume3.03 million shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$2.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cronos Group alerts: Email Address Cronos Group MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside3.3% Downside$2.83 Price TargetShort InterestHealthy3.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.01) to $0.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.23 out of 5 starsMedical Sector2718th out of 2,771 stocksMedicinals & Botanicals Industry28th out of 30 stocks 1.2 Analyst's Opinion Consensus RatingCronos Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCronos Group has only been the subject of 1 research reports in the past 90 days.Read more about Cronos Group's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.02% of the float of Cronos Group has been sold short.Short Interest Ratio / Days to CoverCronos Group has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cronos Group has recently increased by 7.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCronos Group does not currently pay a dividend.Dividend GrowthCronos Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRON. Previous Next 1.9 News and Social Media Coverage News SentimentCronos Group has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Cronos Group this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for CRON on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Cronos Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cronos Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Cronos Group is held by insiders.Percentage Held by InstitutionsOnly 8.71% of the stock of Cronos Group is held by institutions.Read more about Cronos Group's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cronos Group are expected to grow in the coming year, from ($0.01) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cronos Group is -19.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cronos Group is -19.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCronos Group has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cronos Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. About Cronos Group Stock (NASDAQ:CRON)Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Read More CRON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRON Stock News HeadlinesMay 13 at 6:06 PM | msn.comHere’s Why it’s Not Too Late to Buy Cronos Group StockMay 13 at 4:57 AM | americanbankingnews.comCronos Group Inc. (NASDAQ:CRON) to Post Q1 2025 Earnings of $0.03 Per Share, Roth Capital ForecastsMay 11 at 10:36 AM | finance.yahoo.comCronos Group First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | finance.yahoo.comCronos Group Inc (CRON) Surpasses Analyst Revenue Forecasts in Q1 2024May 10, 2024 | investorplace.com7 Massively Undervalued Penny Stocks to Buy for 7-Bagger ReturnsMay 9, 2024 | msn.comCronos Cannabis Company Slashes Losses, Reports Highest Quarterly Net Revenue In Q1 2024May 9, 2024 | investorplace.com7 Cannabis Stocks to Buy for a Smoking-Hot 2024May 9, 2024 | washingtonpost.comCronos: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comCronos Group Reports 2024 First Quarter ResultsMay 7, 2024 | investorplace.comThe 3 Best Meme Stocks to Buy in May 2024May 7, 2024 | globenewswire.comCronos Enters United Kingdom Cannabis MarketMay 1, 2024 | fool.comWhy Canopy Growth, Tilray, and Cronos Group Stocks Just CrateredMay 1, 2024 | msn.comUS to reclassify marijuana as less dangerous drug in historic shiftApril 30, 2024 | finance.yahoo.comNurses Week 2024: Don't Miss These Gift & CE Giveaways for Nurses and Nursing Students!April 30, 2024 | fool.comWhy Cannabis Companies Tilray, Canopy Growth, Cronos, and SNDL Got Really High on TuesdayApril 30, 2024 | proactiveinvestors.comCannabis stocks surge on reports DEA will approve rescheduling of marijuana as lower-risk drugApril 30, 2024 | investorplace.com3 Hot Penny Stocks That Can Rocket 100% in the Blink of an EyeApril 26, 2024 | globenewswire.comCronos Group Inc. to Hold Virtual 2024 Annual Meeting of ShareholdersApril 25, 2024 | globenewswire.comCronos Group Inc. to Hold 2024 First Quarter Earnings Conference Call on May 9, 2024April 25, 2024 | investorplace.comThe Only 3 Cannabis Stocks Sensible Investors Are BuyingApril 23, 2024 | businesswire.comFresh Retail Software Industry Leader Invafresh Announces Appointment of Andrew Cron, PhD as Chief Data OfficerApril 21, 2024 | investorplace.com3 Speculative Penny Stocks That Can Spike to Double Digits in 2024April 16, 2024 | investorplace.com3 Cannabis Penny Stocks to Buy for 3-Bagger ReturnsApril 12, 2024 | investorplace.com7 Penny Stocks That Could Deliver 1,000% Returns by 2029April 9, 2024 | fool.comWhy Marijuana Stocks Got Burnt TodaySee More Headlines Receive CRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cronos Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:CRON CUSIPN/A CIK1656472 Webwww.thecronosgroup.com Phone(416) 504-0004FaxN/AEmployees356Year FoundedN/APrice Target and Rating Average Stock Price Target$2.83 High Stock Price Target$3.00 Low Stock Price Target$2.50 Potential Upside/Downside-3.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,960,000.00 Net Margins-61.31% Pretax Margin-61.53% Return on Equity-3.06% Return on Assets-2.97% Debt Debt-to-Equity RatioN/A Current Ratio28.19 Quick Ratio27.28 Sales & Book Value Annual Sales$87.24 million Price / Sales12.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book1.02Miscellaneous Outstanding Shares382,010,000Free Float374,524,000Market Cap$1.12 billion OptionableOptionable Beta1.11 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. James Andrew McGinness III (Age 45)VP, Controller & Principal Accounting Officer Mr. Shayne J. LaidlawDirector of Investor Relations & StrategyMr. Adam Wagner (Age 41)Senior VP & Head of Cronos Israel Key CompetitorsCanopy GrowthNASDAQ:CGCUSANA Health SciencesNYSE:USNAMind Medicine (MindMed)NASDAQ:MNMDbioteNASDAQ:BTMDAurora CannabisNASDAQ:ACBView All CompetitorsInsiders & InstitutionsCedar Wealth Management LLCBought 22,935 shares on 5/13/2024Ownership: 0.006%Vanguard Group Inc.Bought 12,269 shares on 5/10/2024Ownership: 1.856%MMCAP International Inc. SPCBought 36,900 shares on 5/10/2024Ownership: 0.010%Concurrent Investment Advisors LLCBought 30,301 shares on 5/7/2024Ownership: 0.008%Janney Montgomery Scott LLCBought 101,903 shares on 5/1/2024Ownership: 0.080%View All Insider TransactionsView All Institutional Transactions CRON Stock Analysis - Frequently Asked Questions Should I buy or sell Cronos Group stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CRON shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRON, but not buy additional shares or sell existing shares. View CRON analyst ratings or view top-rated stocks. What is Cronos Group's stock price target for 2024? 3 Wall Street research analysts have issued 12 month target prices for Cronos Group's shares. Their CRON share price targets range from $2.50 to $3.00. On average, they expect the company's share price to reach $2.83 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View analysts price targets for CRON or view top-rated stocks among Wall Street analysts. How have CRON shares performed in 2024? Cronos Group's stock was trading at $2.09 on January 1st, 2024. Since then, CRON shares have increased by 40.2% and is now trading at $2.93. View the best growth stocks for 2024 here. When is Cronos Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CRON earnings forecast. How were Cronos Group's earnings last quarter? Cronos Group Inc. (NASDAQ:CRON) released its earnings results on Thursday, May, 9th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The firm earned $25.29 million during the quarter, compared to the consensus estimate of $24.30 million. Cronos Group had a negative net margin of 61.31% and a negative trailing twelve-month return on equity of 3.06%. During the same quarter in the previous year, the business earned ($0.03) EPS. What other stocks do shareholders of Cronos Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include Tilray (TLRY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and Organigram (OGI). Who are Cronos Group's major shareholders? Cronos Group's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.86%), Mirae Asset Global Investments Co. Ltd. (0.26%), IMC Chicago LLC (0.00%), Janney Montgomery Scott LLC (0.08%), SeaCrest Wealth Management LLC (0.02%) and Madrona Financial Services LLC (0.01%). View institutional ownership trends. How do I buy shares of Cronos Group? Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRON) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe only AI company you should be looking atBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressNo experience to confident trader, meet my student…Wealth Builders InstituteCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOIC Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cronos Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
